Rick Klausner fronts cash for his fungus outfit LifeMine and brings on Nobel laureate to further push cancer discovery
More than three years after launching with a $55 million Series A, fungus player LifeMine Therapeutics is back with a trifecta of new goodies: cash, a prominent investor and a Nobel laureate.
Rick Klausner is leading a $50 million Series B round with his Milky Way Investments for LifeMine, which he also co-founded, as it aims to expand its efforts in bringing fungi to the forefront of drug R&D, the company said Thursday. William Kaelin, who won the 2019 Nobel Prize in Physiology or Medicine for his work in understanding how cells sense and adapt to changes in oxygen, is also joining LifeMine’s board of directors.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.